# A Research Study Comparing Different Ways of Increasing the Dose of NNC0662-0419 in Participants With Obesity

> **NCT07639021** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Novo Nordisk A/S** · enrollment: 233 (actual)

## Conditions studied

- Obesity

## Interventions

- **DRUG:** NNC0662-0419
- **DRUG:** Semaglutide
- **DRUG:** NNC0662-0419 Placebo
- **DRUG:** Semaglutide placebo

## Key facts

- **NCT ID:** NCT07639021
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2026-06-09
- **Primary completion:** 2027-06-14
- **Final completion:** 2027-06-14
- **Target enrollment:** 233 (ACTUAL)
- **Last updated:** 2026-09-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07639021

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07639021, "A Research Study Comparing Different Ways of Increasing the Dose of NNC0662-0419 in Participants With Obesity". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07639021. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*